Silo Pharma Announces NVIDIA Partnership for AI Platform and Advances PTSD Treatment Development
Silo Pharma's subsidiary QwikAgents has joined the NVIDIA Developer Program to enhance its autonomous AI agent platform, aiming to automate business processes. Additionally, Silo is collaborating with Resyca on a nasal spray technology evaluation for SPC-15, an intranasal treatment candidate for PTSD.
Topics: Artificial Intelligence (AI) NVIDIA Developer Program Partnership Pharma